194 patents
Page 6 of 10
Utility
Universal Donor Cells
25 Nov 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca Ramos-Zayas
Filed: 23 Jul 21
Utility
Universal donor cells
23 Nov 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 26 Apr 21
Utility
Messenger Rna Encoding CAS9 for Use In Genome-editing Systems
18 Nov 21
The present disclosure provides optimized mRNAs encoding a site-directed endonuclease for use in a CRISPR/Cas system.
Christian Cobaugh
Filed: 13 May 21
Utility
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
16 Nov 21
The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 15 Jun 17
Utility
Masked Chimeric Antigen Receptor Specific to Tyrosine-protein Kinase Like 7 (PTK7) and Immune Cells Expressing Such
11 Nov 21
Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7.
Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
Filed: 6 May 21
Utility
Compositions and Methods for Delivering Transgenes
11 Nov 21
Provided herein are compositions, methods, and systems for targeted delivery of nucleic acids, including DNA and RNA, to a target cell.
Alan Richard Brooks, Karen Vo
Filed: 17 Oct 19
Utility
Universal Donor Cells
11 Nov 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 26 Apr 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
9 Nov 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 29 Jul 20
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
5 Oct 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 8 Jul 20
Utility
ANTI-PTK7 Immune Cell Cancer Therapy
23 Sep 21
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7+ malignancies.
Jonathan Alexander Terrett, Jason Sagert
Filed: 7 Nov 19
Utility
ANTI-LIV1 Immune Cell Cancer Therapy
23 Sep 21
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1+ malignancies.
Jonathan Alexander Terrett, Jason Sagert
Filed: 7 Nov 19
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
14 Sep 21
The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299.
Mariacarmela Allocca, Akiko Noma, Abraham Scaria
Filed: 18 Jun 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Allogeneic Cell Therapy of B Cell Malignancies Using Genetically Engineered T Cells Targeting CD19
2 Sep 21
A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.
Mark Benton, Tony Ho, Demetrios Kalaitzidis, Ewelina Morawa, Jonathan Alexander Terrett
Filed: 22 Apr 21
Utility
Universal donor cells
31 Aug 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Materials and Methods for Treatment of Amyotrophic Lateral Sclerosis And/or Frontal Temporal Lobular Degeneration
26 Aug 21
The present application provides materials and methods for treating a patient with Amyotrophic Lateral Sclerosis (ALS) and/or Frontaltemporal Lobular Degeneration (FTLD), both ex vivo and in vivo.
Chad Albert Cowan, Ami Meda Kabadi, Ante Sven Lundberg
Filed: 22 Dec 16
Utility
Methods and Compositions for Treating Cancer
26 Aug 21
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 23 Apr 21